RecruitingPhase 2NCT05871021
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital Tuebingen
- Principal Investigator
- Maximilian Niyazi, Prof. Dr.University Hospital Tuebingen, Department of Radiation Oncology
- Intervention
- Dose escalation of radiation dose beyond the therapeutic standard(radiation)
- Enrollment
- 146 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2024 – 2028
Study locations (1)
- Department of Radiation Oncology, Tübingen, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05871021 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland